Rivara S[Author] - Search Results

Year	Number of Results
1959	1
1961	1
1972	1
1997	5
1998	2
1999	1
2000	2
2001	2
2003	6
2004	5
2005	5
2006	6
2007	6
2008	5
2009	5
2010	4
2011	9
2012	6
2013	8
2014	8
2015	12
2016	7
2017	8
2018	5
2019	4
2020	7
2021	6
2022	6
2023	2
2024	3

1

Clathrin-associated AP-1 controls termination of STING signalling.

Liu Y, Xu P, Rivara S, Liu C, Ricci J, Ren X, Hurley JH, Ablasser A. Liu Y, et al. Among authors: rivara s. Nature. 2022 Oct;610(7933):761-767. doi: 10.1038/s41586-022-05354-0. Epub 2022 Oct 19. Nature. 2022. PMID: 36261523 Free PMC article.

2

COPA silences STING.

Rivara S, Ablasser A. Rivara S, et al. J Exp Med. 2020 Nov 2;217(11):e20201517. doi: 10.1084/jem.20201517. J Exp Med. 2020. PMID: 32991673 Free PMC article.

3

Melatonin receptor structure and signaling.

Okamoto HH, Cecon E, Nureki O, Rivara S, Jockers R. Okamoto HH, et al. Among authors: rivara s. J Pineal Res. 2024 Apr;76(3):e12952. doi: 10.1111/jpi.12952. J Pineal Res. 2024. PMID: 38587234 Review.

4

Combined targeting of fatty acid amide hydrolase and melatonin receptors promotes neuroprotection and stimulates inflammation resolution in rats.

Cammarota M, Ferlenghi F, Vacondio F, Vincenzi F, Varani K, Bedini A, Rivara S, Mor M, Boscia F. Cammarota M, et al. Among authors: rivara s. Br J Pharmacol. 2023 May;180(10):1316-1338. doi: 10.1111/bph.16014. Epub 2023 Jan 6. Br J Pharmacol. 2023. PMID: 36526591

5

The Control of Heparanase Through the Use of Small Molecules.

Giannini G, Battistuzzi G, Rivara S. Giannini G, et al. Among authors: rivara s. Adv Exp Med Biol. 2020;1221:567-603. doi: 10.1007/978-3-030-34521-1_23. Adv Exp Med Biol. 2020. PMID: 32274727 Review.

6

Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).

Lodola A, Castelli R, Mor M, Rivara S. Lodola A, et al. Among authors: rivara s. Expert Opin Ther Pat. 2015;25(11):1247-66. doi: 10.1517/13543776.2015.1067683. Epub 2015 Sep 28. Expert Opin Ther Pat. 2015. PMID: 26413912 Review.

7

Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases.

Rivara S, Milazzo FM, Giannini G. Rivara S, et al. Future Med Chem. 2016 Apr;8(6):647-80. doi: 10.4155/fmc-2016-0012. Epub 2016 Apr 8. Future Med Chem. 2016. PMID: 27057774 Free article. Review.

8

Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations.

Lodola A, Callegari D, Scalvini L, Rivara S, Mor M. Lodola A, et al. Among authors: rivara s. Methods Mol Biol. 2020;2114:307-337. doi: 10.1007/978-1-0716-0282-9_19. Methods Mol Biol. 2020. PMID: 32016901 Review.

9

Homology models of melatonin receptors: challenges and recent advances.

Pala D, Lodola A, Bedini A, Spadoni G, Rivara S. Pala D, et al. Among authors: rivara s. Int J Mol Sci. 2013 Apr 12;14(4):8093-121. doi: 10.3390/ijms14048093. Int J Mol Sci. 2013. PMID: 23584026 Free PMC article. Review.

10

Pharmacokinetic and pharmacodynamic evaluation of ramelteon : an insomnia therapy.

Spadoni G, Bedini A, Lucarini S, Mor M, Rivara S. Spadoni G, et al. Among authors: rivara s. Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1145-56. doi: 10.1517/17425255.2015.1045487. Epub 2015 May 8. Expert Opin Drug Metab Toxicol. 2015. PMID: 25956235 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

139 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Results by year